Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows a mix of positive and negative factors. While there are promising product developments and strategic investments, the revenue guidance indicates a decline, and there are uncertainties in regulatory approvals. The Q&A section reflects cautious optimism but also highlights concerns about execution and competition. The strategic plan suggests potential growth, but the lack of strong financial metrics or new partnerships tempers expectations, resulting in a neutral sentiment.
Key Financial Performance
Growth Products Revenue $850 million in Q1 2026, up 12% year-over-year. The increase is attributed to a shift in commercial costs from the MS portfolio to growth products.
SPINRAZA Revenue Declined slightly in Q1 2026 due to timing of shipments and a one-off VAT event in Europe in the prior year. However, the new high-dose SPINRAZA has been approved in multiple regions, which is expected to improve competitiveness.
LEQEMBI Revenue $168 million in Q1 2026, up 74% year-over-year. Growth driven by sequential market growth in the U.S., Japan, and China, with strong uptake in China.
SKYCLARYS Revenue $151 million in Q1 2026, up 22% year-over-year. Growth driven by global patient demand and expansion to 35 countries.
Total Revenue $2.5 billion in Q1 2026, up 2% year-over-year. Growth attributed to strong performance of growth products.
GAAP Diluted EPS $2.15 in Q1 2026, up 31% year-over-year. Increase driven by strong revenue performance and cost discipline.
Non-GAAP Diluted EPS $3.57 in Q1 2026, up 18% year-over-year. Growth attributed to disciplined financial management and strong commercial execution.
Free Cash Flow $594 million in Q1 2026. Strong cash flow generation supports business investments and the expected Apellis transaction.
Non-GAAP Core Operating Expenses Approximately $1.1 billion in Q1 2026. Reflects investments in late-stage pipeline development and product launches.
LEQEMBI Market Leadership LEQEMBI remains the market leader by total patient share in the U.S., Japan, and China, supported by strong sequential market growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
High-dose SPINRAZA: Approved in the U.S., Japan, and Europe. Positive feedback from launched countries. Expected to enhance competitiveness and efficacy in the SMA market.
LEQEMBI: End market revenue of $168 million in Q1 2026, up 74% YoY. Significant patient retention rates (80% at 18 months, 70% at 2 years). PDUFA date for subcutaneous induction set for May 24, 2026.
SKYCLARYS: Global revenue of $151 million in Q1 2026, up 22% YoY. Available in 35 countries, with growth driven by ex-U.S. markets.
China market expansion: Acquired China rights for felzartamab to strengthen presence in the world's second-largest pharmaceutical market. Focus on IgAN and nephrology.
Revenue growth: Total revenue of $2.5 billion in Q1 2026, up 2% YoY. Growth products generated $851 million, up 12% YoY.
Cost management: Non-GAAP core operating expenses of $1.1 billion in Q1 2026. Maintained cost discipline while supporting late-stage pipeline and product launches.
Apellis acquisition: Expected to close in Q2 2026. Adds SYFOVRE and EMPAVELI to Biogen's portfolio, enhancing growth in immunology and rare diseases. Anticipated to be accretive to EPS by 2027.
Pipeline development: Significant progress in late-stage pipeline with multiple data readouts expected in 2026 and beyond. Focus on lupus, nephrology, and rare diseases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue and Profit Decline: The company faced four years of declining revenue and profit until 2023, which required significant cost-cutting and strategic investment shifts to stabilize the business.
SPINRAZA Revenue Decline: SPINRAZA experienced a slight revenue decline due to shipment timing and a one-off VAT event in Europe, highlighting the challenges of managing lumpy revenue streams in international markets.
Competitive Pressures in SMA Market: The SMA market remains highly competitive, and the company relies on the high-dose SPINRAZA to maintain competitiveness, emphasizing the need for efficacy to retain market share.
Regulatory and Market Challenges for LEQEMBI: The company is working to improve the care pathway for LEQEMBI, including regulatory approvals and patient convenience, to enhance its competitive profile against Kisunla.
Integration Risks with Apellis Acquisition: The proposed acquisition of Apellis introduces integration risks, including aligning teams and resources while ensuring the acquisition is accretive by 2027.
Nephrology Market Competition: The nephrology market is becoming increasingly competitive, with multiple companies recruiting and launching products, which could impact Biogen's ability to establish a strong presence.
China Market Expansion Challenges: Biogen's relatively small presence in China poses challenges as it seeks to expand in the world's second-largest pharmaceutical market, particularly with felzartamab.
Execution Risks: The company acknowledges that 90% of business success depends on execution, emphasizing the importance of effective implementation of its strategic plans.
Policy and Macroeconomic Uncertainty: Potential tariffs and macroeconomic factors could impact the business, although the company believes its U.S. manufacturing footprint and supply chain provide some resilience.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Biogen expects the acquisition of Apellis to be accretive in 2027 and to materially increase Biogen's EPS outlook. The acquisition is anticipated to allow Biogen to start growing now, with a pipeline coming on a growing business.
Product Launches and Approvals: High-dose SPINRAZA has been approved in the U.S., Japan, and Europe, with positive feedback from these markets. LEQEMBI has a PDUFA date of May 24 for the induction subcutaneous, which is expected to improve patient convenience and competitive profile. SKYCLARYS is now available in 35 countries, with growth expected from ex-U.S. markets.
Pipeline Development: Biogen anticipates multiple data readouts from its late-stage pipeline starting this year and extending through the end of the decade. Key readouts include Phase III studies for litifilimab, felzartamab, and Zorevunersen. The company expects significant data-related inflection points in 2026.
Market Expansion: Biogen has acquired China rights for felzartamab, aiming to build its business in China, the world's second-largest pharmaceutical market. This acquisition is expected to enhance Biogen's nephrology franchise.
Financial Guidance: Biogen expects to fund the Apellis transaction with $3.6 billion of cash and $2 billion from bank borrowings, with plans to repay the borrowings by the end of 2027. The company maintains its revenue outlook for 2026 and expects strong cash flow generation to support future growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the latest views on BIIB080 data and its potential impact on administration forms?
A:BIIB080 is an antisense oligonucleotide targeting tau to reduce both intracellular and extracellular tau. Phase Ib trials showed encouraging tau reduction, prompting a proof-of-concept study (CELIA). The CELIA readout will determine if tau reduction translates into clinical benefits, specifically cognition. Several dosing regimens and treatment frequencies are being explored. Data is expected midyear and will be communicated at upcoming forums. Intrathecal delivery is being used, but other delivery options are being explored, including through the recent acquisition of Alcyone.
Q:What is the filing strategy for litifilimab in SLE and CLE?
A:Two Phase III trials in SLE are expected to read out this year, with a CLE trial readout early next year. Filing strategy is not finalized, but the current plan is to package the data together. If one SLE trial is positive and the other trends, the totality of data will be considered, as there is precedent for such cases. Litifilimab has received breakthrough designation for CLE and has shown positive Phase II data in CLE.
Q:How does Biogen rank external innovation versus internal R&D and SG&A investments post-Apellis acquisition?
A:Biogen is focusing on early-stage development and research to strengthen its pipeline, which is currently thin in that area. Collaborations in immunology and other areas have been established. M&A will be more opportunistic rather than proactive, as the Apellis transaction and existing pipeline reduce the immediate need for aggressive M&A.
Q:What are the expectations for BIIB080 Phase II results and its potential continuation?
A:The CELIA trial was downsized from 700 to 400 patients based on Phase Ib results. The trial is designed to test the hypothesis that tau reduction translates to clinical efficacy, with CDR-Sum of Boxes as the primary endpoint. The totality of data, including tau reduction and cognition improvement, will be evaluated. The study is pioneering, and the bar for continuation is not necessarily high but must show signs of clinical benefit.
Q:What is the adoption status of blood-based biomarkers for LEQEMBI and patient transitions from Kisunla?
A:Blood-based biomarkers are increasingly used for confirmation, supported by a PCP pilot and CMS reimbursement. Awareness is high, and adoption is expected to grow. Patients completing Kisunla are reaching their 18-month mark, and some physicians are considering switching them to LEQEMBI maintenance, although no data supports this yet.
Q:What is the competitive landscape and positioning of SYFOVRE in geographic atrophy?
A:SYFOVRE shows a 42% reduction in lesion growth and long-term data indicating a 1.5-year slowdown in progression. Competitive products like IZERVAY and others targeting C5 are emerging, but SYFOVRE's targeted delivery to the eye and extensive data create a competitive advantage. Commercially, SYFOVRE benefits from its 5-year data, which builds confidence among physicians and patients.
Q:What are the spending and strategic plans for SYFOVRE's franchise growth?
A:Biogen plans to leverage synergies with existing capabilities and focus on patient activation through education and direct-to-consumer advertising. The company will analyze current tactics and reallocate resources to drive growth. Biogen's experience in launching multiple products positions it to support SYFOVRE effectively.
Q:How does high-dose SPINRAZA impact the franchise and patient switching?
A:High-dose SPINRAZA has seen strong interest, with 20% of the patient base submitting start forms within a month of launch. Patients are switching from competitors and adding on to ZOLGENSMA. The high-dose option is expected to stabilize and potentially grow the franchise, with additional support from devices like Alcyone and once-yearly intrathecal options in development.
Q:What are the drivers of SKYCLARYS growth and its future potential?
A:SKYCLARYS growth is driven by patient finding and activation efforts. The U.S. market is seeing slower progress due to older patients and single-prescription doctors. Ex-U.S., patient demand is increasing, with more patients on early access programs awaiting reimbursement. Revenue may be lumpy as patients transition to full reimbursement.
Q:What is the potential for BIIB080 in other tauopathies?
A:BIIB080 shows promise in primary tauopathies due to its ability to reduce tau. The upcoming Phase II results will inform the strategy for expanding into other tauopathies, focusing on tau reduction and brain region-specific effects.
Q:What is the commercial opportunity for felzartamab in AMR and other kidney diseases?
A:Felzartamab targets CD38-positive plasma cells and shows potential in AMR, with a total addressable market of $2-3 billion. The drug's mechanism and durability of treatment position it as a competitive option in kidney diseases, with the first readout expected in 2027.
Q:What are the real-world treatment persistence trends for LEQEMBI and the impact of subcutaneous versions?
A:Real-world data shows patients and neurologists prefer to stay on LEQEMBI due to its dual target and progressive disease nature. Subcutaneous maintenance simplifies treatment and offers optionality, with an FDA decision on subcutaneous initiation expected soon. This could significantly impact patient journey and treatment persistence.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers on the filing strategy for litifilimab, stating they do not usually comment on it and will communicate more as studies read out. Additionally, they were vague about the specific criteria for advancing BIIB080, emphasizing the totality of data without clear thresholds for continuation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Biogen
Dravet syndrome
EMPAVELI nephrology
Head
III study
Japan
LEQEMBI
PDUFA date
Phase III
SKYCLARYS
SPINRAZA
SYFOVRE
acquisition
benefit
country
demand
disease
dose
efficacy
felzartamab
launch
lesion
litifilimab
lot
nephrology franchise
non
opportunity
outlook
patient
portfolio
product
readout
right
salanersen
slide
stage
treatment
BIIB Transcript
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call summary shows a mix of positive and negative factors. While there are promising product developments and strategic investments, the revenue guidance indicates a decline, and there are uncertainties in regulatory approvals. The Q&A section reflects cautious optimism but also highlights concerns about execution and competition. The strategic plan suggests potential growth, but the lack of strong financial metrics or new partnerships tempers expectations, resulting in a neutral sentiment.
Canadian Net Real Estate Investment Trust (NET.UN:CA) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings call highlights strong financial performance with increased FFO and NOI, driven by property acquisitions and rent increases. Despite risks like rising interest rates and REIT sector volatility, the company's strategic focus on high-quality acquisitions and disciplined growth is promising. The Q&A session reveals a positive sentiment with clarity in management's responses, emphasizing their ability to act on opportunities. Overall, the company's financial health and strategic growth initiatives suggest a positive stock price movement.
Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
BIIB Slides
BIIB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
